Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

OBJECTIVES: The PALACE 4 trial evaluated apremilast monotherapy in patients with active PsA who were DMARD-naive. METHODS: Eligible patients were randomized (1:1:1) to placebo, apremilast 20 mg twice a day or apremilast 30 mg twice a day. At week 16 or 24, placebo patients were rerandomized to aprem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatology (Oxford)
Main Authors: Wells, Alvin F, Edwards, Christopher J, Kivitz, Alan J, Bird, Paul, Nguyen, Dianne, Paris, Maria, Teng, Lichen, Aelion, Jacob A
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6014136/
https://ncbi.nlm.nih.gov/pubmed/29635379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/key032
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados